Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Three RNAi-Related Patent Applications: Jan 24, 2008

Premium
Title: siRNA Targeting Connective Tissue Growth Factor
 
Number: 20080015114
 
Filed: March 29, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CTGF.”
 

 
Title: Inhibition of Expression of Huntingtin Gene
 
Number: 20080015158
 
Filed: April 30, 2004 PCT Filed: April 30, 2004
 
Lead Inventor: Kanazawa Ichiro, University of Tokyo
 
The patent application, its abstract states, claims “methods for suppressing the huntingtin gene expression by using a double-stranded RNA, huntingtin gene expression inhibitors to suppress the huntingtin gene expression, and preventives and/or remedies of Huntington's disease. Targeting against a specific sequence of mRNA immediately upstream of CAG repeats in HD genes of Huntington's disease, the huntingtin gene expression is suppressed by using a dsRNA homologous to the sequence. In this invention, a short siRNA having [base pairs] as short as around 21-23 … can be effectively used as the dsRNA [that is] homologous to a specific RNA sequence in a region at immediately upstream of CAG repeats,” the abstract adds. “The dsRNA of this present invention can be used as a huntingtin gene expression inhibitor, or a preventive and/or a remedy of Huntington's disease by administering or introducing into a living body or a living cell in mammals for the prevention and/or treatment of Huntington's disease.”
 

 
Title: RNAi Modulation of TGF-Beta and Therapeutic Uses Thereof
 
Number: 20080015161
 
Filed: March 15, 2007
 
Lead Inventor: Hans-Peter Vornlocher, Alnylam
 
The invention, the patent application’s abstract states, “concerns methods of treatment using transforming growth factor beta modulators. More specifically, the invention concerns methods of treating disorders associated with undesirable TGF-beta signaling, by administering short interfering RNA which down-regulate the expression of TGF-beta, and agents useful therein.”

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.